SciSparc Receives FDA Approval To Initiate Phase IIb Clinical Trial Of SCI-110 In Tourette Syndrome Treatment
Portfolio Pulse from Benzinga Newsdesk
SciSparc has received FDA approval to begin a Phase IIb clinical trial for its drug SCI-110, aimed at treating Tourette Syndrome. This marks a significant step forward in the company's drug development process.
September 23, 2024 | 12:18 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
SciSparc has received FDA approval to initiate a Phase IIb clinical trial for SCI-110, targeting Tourette Syndrome. This approval is a positive development for the company, potentially boosting investor confidence.
The FDA approval for a Phase IIb trial is a critical milestone in drug development, indicating progress and potential future revenue if the drug is successful. This news is likely to positively impact SciSparc's stock price in the short term as it reflects advancement in their product pipeline.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100